Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome

Ya Min Yang, Chen Yang Hsu, Chao Chih Lai, Ming Fang Yen, Paul S. Wikramaratna, Hsiu Hsi Chen, Tsung Hsi Wang

研究成果: 雜誌貢獻文章

17 引文 斯高帕斯(Scopus)

摘要

To date, 1841 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 652 deaths. We used a publically available case line list to explore the effect of relevant factors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016. A Bayesian Weibull proportional hazards regression model was used to assess the effect of comorbidity, age, epidemic period and sex on the fatality rate of MERS cases and its variation across countries. The crude fatality rate of MERS cases was 32.1% (95% credibility interval (CI): 29.9%, 34.3%). Notably, the incremental change of daily death rate was most prominent during the first week since disease onset with an average increase of 13%, but then stabilized in the remaining two weeks when it only increased 3% on average. Neither sex, nor country of infection were found to have a significant impact on fatality rates after taking into account the age and comorbidity status of patients. After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95% CI: 2.57, 5.67)).
原文英語
文章編號11307
期刊Scientific Reports
7
發行號1
DOIs
出版狀態已發佈 - 十二月 1 2017

ASJC Scopus subject areas

  • General

指紋 深入研究「Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome」主題。共同形成了獨特的指紋。

  • 引用此

    Yang, Y. M., Hsu, C. Y., Lai, C. C., Yen, M. F., Wikramaratna, P. S., Chen, H. H., & Wang, T. H. (2017). Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. Scientific Reports, 7(1), [11307]. https://doi.org/10.1038/s41598-017-10402-1